While boasting a third-quarter revenue beat, biotech firm Moderna (MRNA) reported an overwhelmingly higher-than-expected loss of $9.53 per share. Its shares find themselves under pressure over weakening COVID-19 vaccine demand. Moderna’s Chief Financial Officer Jamey Mock joins Yahoo Finance’s Anjalee Khemlani to discuss the company’s forward strategy.
Mock notes that the company aims to “break-even by 2026,” acknowledging investors’ concerns. Mock’s optimism for the 2026 deadline is based on “organic growth opportunity” in the late-stage product pipeline with plans to introduce RSV and flu vaccines in the coming years.
For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
#youtube #Moderna #yahoofinance
Subscribe to Yahoo Finance: https://yhoo.it/2fGu5Bb
About Yahoo Finance:
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.
Yahoo Finance Plus: With a subscription to Yahoo Finance Plus get the tools you need to invest with confidence. Discover new opportunities with expert research and investment ideas backed by technical and fundamental analysis. Optimize your trades with advanced portfolio insights, fundamental analysis, enhanced charting, and more.
To learn more about Yahoo Finance Plus please visit: https://yhoo.it/33jXYBp
Connect with Yahoo Finance:
Get the latest news: https://yhoo.it/2fGu5Bb
Find Yahoo Finance on Facebook: http://bit.ly/2A9u5Zq
Follow Yahoo Finance on Twitter: http://bit.ly/2LMgloP
Follow Yahoo Finance on Instagram: http://bit.ly/2LOpNYz
Follow Yahoo Finance Premium on Twitter: https://bit.ly/3hhcnmV
Amen sister!